Claims
- 1. An adipose tissue-derived adult stem cell that is differentiated to express at least one characteristic of an adipocyte and which contains a substantially greater amount of extracellular matrix proteins than a mature isolated adipocyte.
- 2. An adipose tissue-derived adult stem cell that is differentiated to express at least one characteristic of an adipocyte and which contains a significantly greater amount of extracellular matrix proteins than a mature isolated adipocyte.
- 3. An adipose tissue-derived adult stem cell that is differentiated to express at least one characteristic of an adipocyte and which contains a substantially smaller amount of lipid than a mature isolated adipocyte.
- 4. An adipose tissue-derived adult stem cell that is differentiated to express at least one characteristic of an adipocyte and which contains a significantly smaller amount of lipid than a mature isolated adipocyte.
- 5. The cell of claim 1, wherein the extracellular matrix protein is collagen.
- 6. The cell of claim 2, wherein the extracellular matrix protein is collagen.
- 7. The cell of any of claims 1-6, wherein the cell is human.
- 5. The cell of any of claims 1-6, wherein the cell is modified with a nucleic acid.
- 6. The cell of any of claims 1-6, wherein the cell is modified with a chemical probe.
- 7. A method for expanding the growth of an isolated adipose tissue-derived stem cell comprising:
(a) plating the cells in a single container at varying densities in a growth maintenance medium comprising a chemically defined cell culture medium without enzymatic digestion and re-plating of the cells; and (b) incubating the cells for a growth period to optimize the production of extracellular matrix.
- 8. A method for differentiating an adipose tissue-derived stem cell into a cell that possesses at least one characteristic of an adipocyte, comprising:
(a) plating the cells at varying densities in a single container in a growth maintenance medium comprising a chemically defined cell culture medium without enzymatic digestion and re-plating of the cells; (b) incubating the cells for a cell growth period to optimize the production of extracellular matrix; (c) replacing the growth maintenance medium with an adipocyte differentiation medium comprising a defined cell culture medium having or supplemented with a concentration of a peroxisome proliferator-activated receptor gamma (PPARγ) agonist that is not a thiazolidinedione (d) incubating the cells; (e) replacing the adipocyte differentiation medium with a growth maintenance medium; (f) incubating the cells; and (g) harvesting the cells
- 9. A method for differentiating an adipose tissue-derived stem cell into a cell that possesses at least one characteristic of an adipocyte, comprising:
(a) plating the cells at varying densities in a single container in a growth maintenance medium comprising a chemically defined cell culture medium without enzymatic digestion and re-plating of the cells; (b) replacing the growth maintenance medium with an adipocyte differentiation medium comprising a defined cell culture medium having or supplemented with a concentration of a peroxisome proliferator-activated receptor gamma (PPARγ) agonist that is not a thiazolidinedione (c) incubating the cells; (d) replacing the adipocyte differentiation medium with a growth maintenance medium; (f) incubating the cells for a growth period to optimize the production and size of lipid vacuoles; and (g) harvesting the cells
- 10. A method for differentiating an adipose tissue-derived stem cell into a cell that possesses at least one characteristic of an adipocyte, comprising:
(a) plating the cells at varying densities in a single container in a growth maintenance medium comprising a chemically defined cell culture medium without enzymatic digestion and re-plating of the cells; (b) incubating the cells for a cell growth period to optimize the production of extracellular matrix; (c) replacing the growth maintenance medium with an adipocyte differentiation medium comprising a defined cell culture medium having or supplemented with a concentration of a peroxisome proliferator-activated receptor gamma (PPARγ) agonist that is not a thiazolidinedione (d) incubating the cells; (e) replacing the adipocyte differentiation medium with a growth maintenance medium; (f) incubating the cells for a growth period to optimize the production and size of lipid vacuoles; and (g) harvesting the cells
- 11. A method for developing a three dimensional biomaterial matrix containing the adipose tissue-derived stem cells of any of claims 1-4, wherein the cells are capable of generating an adipose tissue depot upon implantation into a host recipient.
- 12. The method of claim 11, wherein the biomaterial matrix is selected from the group consisting of include poly-lactic acid, poly-glycolic acid, alginate, and a collagen type derivatives.
- 13. The method of claim 12, further comprising a chemical inducing factor.
- 14. The method of claim 13, wherein the chemical inducing factor comprises a protein, lipid, carbohydrate, polypeptide, nucleic acid or hormone.
- 15. The method of claim 13, wherein the chemical inducing factor enhances the adherence, growth, differentiation, proliferation, vascularization and three-dimensional modeling of adipose tissue-derived stem cells into a soft tissue or adipose tissue depot either in vivo or ex vivo.
- 16. The method of claim 13, wherein the chemical inducing factor comprises monobutyrin, a thiazolidinedione, a glucocorticoid, or long chain fatty acid.
- 17. The method of claim 13, wherein the chemical inducing factor comprises indomethacin or an indomethacin derivative.
- 18. The method of claim 13, wherein the chemical inducing factor is at a concentration of 10−9 to 10−3 M.
- 19. The method of claim 12, further comprising an exogenous growth factor.
- 20. The method of claim 19, wherein the exogenous growth factor comprises a cytokine, vascular endothelial growth factor, fibroblast growth factor (beta), bone morphogenetic protein 4, bone morphogenetic protein 7, insulin, an insulin analogue, leptin, or growth hormone.
- 21. The method of claim 19, wherein the exogenous growth factor is at a concentration of 1 to 1000 ng/ml.
- 22. The cell of any of claims 1-6 implanted into an immunodeficient rodent.
- 23. The cell of any of claims 1-6 further comprising a label with a probe.
- 24. The cell of claim 23, wherein the probe is adenoviral, retroviral, or fluorescent.
- 25. The cell of any of claims 1-6, implanted into a host.
- 26. The cell of claim 25 wherein the host is in need of tissue repair.
- 27. The cell of claim 26, wherein the host in need of tissue cosmesis.
- 28. The cell of any of claims 1-6, that is allowed to differentiate in vivo.
- 29. A differentiated adipose-tissue derived cell that contains a substantially greater amount of collagen than a mature isolated adipocyte.
- 30. A differentiated adipose-tissue derived cell that contains a significantly greater amount of collagen than a mature isolated adipocyte.
- 31. The cell of claim 29 that is used in tissue cosmesis.
- 32. The cell of claim 30 that is used in tissue cosmesis.
- 33. The cell of claim 29 that is used in tissue repair.
- 34. The cell of claim 30 that is used in tissue repair.
CROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims priority to U.S. Provisional Application No. 60/370,089 filed on Apr. 4, 2002.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60370089 |
Apr 2002 |
US |